Loading organizations...
§ Private Profile · Seattle, WA, USA
Healthcare diagnostics provider operating testing laboratories, offering blood, radiology, and molecular testing across multiple.
Integrated Diagnostics Holdings (IDH) operates a network of testing laboratories providing comprehensive diagnostic services across multiple countries, headquartered in Cairo, Egypt. The publicly traded company, listed on the London Stock Exchange in 2015 with a $668 million market capitalization, offers a wide array of services including blood tests, radiology, and molecular testing for conditions like diabetes and genetic disorders. IDH performs over 27 million diagnostic tests annually through more than 500 branches in Egypt, Jordan, Nigeria, and Sudan, providing access to over 2,000 test types. The company's leadership includes CEO Dr. Hend El Sherbini, with board members such as Lord St John of Bletso, Sherif El Zeiny, and Hussein Choucri. A 25% stake in the company remains family-owned. Integrated Diagnostics was founded in 1979 by Moamena Kamel, MD.
Integrated Diagnostics has raised $135.3M across 6 funding rounds.
Integrated Diagnostics has raised $135.3M in total across 6 funding rounds.
Integrated Diagnostics has raised $135.3M across 6 funding rounds. Most recently, it raised $6.0M Series C in December 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2016 | $6M Series C | — | InterWest, Baird Capital, Interwest Partners | Announced |
| Apr 29, 2014 | $47.3M Debt Financing | Michael Liang | Alexandria Venture Investments, Interwest Partners, Steve Denelsky | Announced |
| Apr 1, 2014 | $32M Series B | — | Arboretum Ventures, Baird Capital, Endeavor Venture Funds, InterWest | Announced |
| Feb 1, 2012 | $10M Series A | — | InterWest, BioTechCube Luxembourg, Interwest Partners | Announced |
| Jul 22, 2010 | $10M Series A Plus | — | Patrizia Luchetta | Announced |
| Oct 1, 2009 | $30M Series A | Interwest Partners | InterWest, Dievini Hopp Biotech Holding | Announced |
Integrated Diagnostics has raised $135.3M in total across 6 funding rounds.
Integrated Diagnostics's investors include InterWest, Baird Capital, InterWest Partners, Michael Liang, Alexandria Venture Investments, Steve DeNelsky, Arboretum Ventures, Endeavor Venture Funds, BioTechCube Luxembourg, Patrizia Luchetta, dievini Hopp Biotech holding.
Integrated Diagnostics Holdings (IDH) is a leading consumer healthcare company specializing in medical diagnostics, operating over 600 branches across Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan.[1][2] It provides more than 3,000 diagnostic tests—from routine checks like cholesterol, diabetes, and pregnancy screening to advanced services in immunology, molecular biology, radiology (MRI, CT, ultrasound), and over 2,000 pathology tests—serving patients and healthcare providers in the Middle East and Africa.[1][2][3] IDH solves critical gaps in accessible, high-quality diagnostics in underserved regions, emphasizing patient-focused care, international accreditations (e.g., CAP, ISO), and a scalable Hub-Spoke-Spike model for expansion; it went public in 2015 with a current market cap of about $0.24B.[1][2]
The company demonstrates strong growth, with a 21% compound annual revenue growth rate from 2015-2020, delivering over 27 million tests in FY2020 alone, and continues expanding via mergers, acquisitions, and financing like IFC's $45M package in 2021.[3]
Founded in 1979 in Giza, Egypt, by Moamena Kamel, MD, a professor of immunology with a PhD from Cairo University, IDH began as a network of testing laboratories addressing diagnostic needs in the region.[1][3] Kamel's expertise drove early focus on quality immunology and pathology services. The company evolved under family leadership, now proudly woman-led by her daughter, Dr. Hend El Sherbini, who brought management acumen to scale operations beyond doctor-led models typical in healthcare.[3]
Pivotal moments include aggressive expansion through M&A to over 500 branches by 2020, a successful IPO on May 14, 2015, and a key role in COVID-19 testing in Egypt and Jordan, highlighting its infrastructure for health crises.[1][3] International backing, such as IFC training and financing, fueled further growth into new countries and services.[3]
IDH rides the wave of digitally enabled diagnostics and telemedicine growth in emerging markets, where rising chronic diseases (diabetes, hepatitis) and post-pandemic demand for accessible testing amplify needs in the Middle East and Africa.[1][3] Timing aligns with healthcare digitization—molecular testing, radiology tech—and urbanization driving demand for scalable labs over fragmented providers.[2][3]
Market forces like population growth, limited public infrastructure, and IFC/World Bank support favor IDH's model, positioning it as a private-sector leader in regional health resilience (e.g., COVID response).[3] It influences the ecosystem by setting quality benchmarks, expanding geographic access, and promoting ethical standards, enabling better disease management and attracting investment to diagnostics infrastructure.[2][3]
IDH is poised for accelerated expansion, leveraging its $45M IFC financing to deepen footprints in existing markets and add services like advanced genomics.[3] Trends like AI-enhanced diagnostics, rising MEA healthcare spending, and climate/health intersections will shape its path, potentially boosting efficiency and test volumes.[2]
Its influence may evolve from regional dominator to pan-African exporter of best practices, sustaining 20%+ growth if it navigates economic volatility—cementing its role as the trusted backbone for millions' health in underserved areas.[1][3]